Comparison · NCT02659020-e2e42675
Phase 2: Olaratumab + Gemcitabine + Docetaxel (Olaratumab-naive) vs Phase 2: Olaratumab + Gemcitabine + Docetaxel (Olaratumab Pre-treated): Phase 2: Number of Participants With Treatment Emergent Anti-Olaratumab Antibodies
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Phase 2: Olaratumab + Gemcitabine + Docetaxel (Olaratumab-naive) vs Phase 2: Olaratumab + Gemcitabine + Docetaxel (Olaratumab Pre-treated): Phase 2: Number of Participants With Treatment Emergent Anti-Olaratumab Antibodies. Trial comparisons, record NCT02659020-e2e42675. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02659020-e2e42675
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0 | 0.0475 | wilson | |
| Risk in group 2 | 0 | 0 | 0.082 | wilson | |
| Risk difference, group 1 minus group 2 | 0 | -0.082 | 0.0475 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat | from the risk difference interval | the two groups' risks are equal |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Phase 2: Olaratumab + Gemcitabine + Docetaxel (Olaratumab-naive) | This cohort included participants who never received olaratumab prior to enrollment. Participants received intravenous infusions of olaratumab loading dose 20 mg/kg on days 1, 8 of cycle 1 followed by 15 mg/kg on days 1, 8 of all subsequent cycles in combination with gemcitabine 900 mg/m\^2 on days 1, 8 and docetaxel 75 mg/m\^2 on day 8 of a 21-day cycle until disease progression, unacceptable toxicity, death, or other discontinuation criteria were met. | 0 | 77 | OG000 |
| Group 2 | Phase 2: Olaratumab + Gemcitabine + Docetaxel (Olaratumab Pre-treated) | This cohort included participants who received commercially available olaratumab prior to enrollment. Participants received intravenous infusions of olaratumab loading dose 20 mg/kg on days 1, 8 of cycle 1 followed by 15 mg/kg on days 1, 8 of all subsequent cycles in combination with gemcitabine 900 mg/m\^2 on days 1, 8 and docetaxel 75 mg/m\^2 on day 8 of a 21-day cycle until disease progression, unacceptable toxicity, death, or other discontinuation criteria were met. | 0 | 43 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Phase 2: Number of Participants With Treatment Emergent Anti-Olaratumab Antibodies
- Description
- Number of Participants with Treatment Emergent Anti-Olaratumab Antibodies
- Time frame
- Baseline through Follow-Up (Up to 38 Months)
- Population
- Phase 2: All randomized participants who received at least one dose of Olaratumab and had evaluable immunogenicity data.
Source ClinicalTrials.gov
Trial
- Title
- A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma
- NCT number
- NCT02659020
- Phases
- PHASE1, PHASE2
- Conditions
- Soft Tissue Sarcoma
- Interventions
- Olaratumab, Gemcitabine, Docetaxel, Placebo
- Lead sponsor
- Eli Lilly and Company
- Results first posted
- 2021-10-11
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02659020?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02659020-e2e42675